Medicine

A “paradox and setback” forced EPFL scientists to dig deeper when seeking a means to boost the power of immunotherapy in lung cancer. Understanding the problem – and finding the solution – has led to a promising potential therapy for some patients.

Researchers at ETH Zurich have developed a molecule that fluoresces where new tissue is forming in the body. Alongside helping to detect tumours, the molecule could play a significant role in research of wound healing disorders.

EPFL scientists have devised a new method that can speed up the real-time observation capabilities of cryo-electron microscopy.

The Lausanne University Hospital (CHUV) and EPFL teamed up to develop a new test that’s sensitive enough to measure the amount of SARS-CoV-2 neutralizing antibodies present in the bloodstream. The scientists’ discovery, published in the prestigious Science Translational Medicine, opens promising new avenues for tracking immunity acquired by infection or vaccination. With this test, experts can measure the level of protection against variants of the virus and monitor their prevalence over time.

Artificial intelligence (AI) is able to recognise the biological activity of natural products in a targeted manner, as researchers at ETH Zurich have demonstrated. Moreover, AI helps to find molecules that have the same effect as a natural substance but are easier to manufacture. This opens up huge possibilities for drug discovery, which also have potential to rewrite the rulebook for pharmaceutical research.

In the laboratories of PSI, researchers are producing proteins of the novel coronavirus Sars-CoV-2. The University Hospital of Zurich is using these in a long-term study to investigate how many people in Switzerland have actually been infected with the virus.